In this episode of Divergent States, 3L1T3 sits down with Betty Aldworth, the new co-president of MAPS, as she steps into shared leadership with Ismail Ali following Rick Doblin’s four-decade run. Betty brings decades of experience in drug policy reform, from Colorado’s 2012 cannabis legalization campaign to leading Students for Sensible Drug Policy, and now helps guide MAPS through one of the movement’s most pivotal moments: the FDA’s rejection of Lycos Therapeutics’ MDMA-assisted therapy ap...
All content for Divergent States is the property of Divergent States and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this episode of Divergent States, 3L1T3 sits down with Betty Aldworth, the new co-president of MAPS, as she steps into shared leadership with Ismail Ali following Rick Doblin’s four-decade run. Betty brings decades of experience in drug policy reform, from Colorado’s 2012 cannabis legalization campaign to leading Students for Sensible Drug Policy, and now helps guide MAPS through one of the movement’s most pivotal moments: the FDA’s rejection of Lycos Therapeutics’ MDMA-assisted therapy ap...
Kyrsten Sinema on Psychedelics, Policy, and Veterans: Inside the New Bipartisan Movement
Divergent States
33 minutes
5 months ago
Kyrsten Sinema on Psychedelics, Policy, and Veterans: Inside the New Bipartisan Movement
In this exclusive interview, former U.S. Senator Kyrsten Sinema joins Divergent States to discuss the future of psychedelic medicine in American healthcare. From Ibogaine and PTSD to policy reform and bipartisan collaboration, Sinema opens up about her firsthand exposure to the healing potential of psychedelics through veterans' experiences - and why the time to act is now. We explore how veterans are pushing the policy frontier, what FDA and CMS approval would mean, and why even critics of t...
Divergent States
In this episode of Divergent States, 3L1T3 sits down with Betty Aldworth, the new co-president of MAPS, as she steps into shared leadership with Ismail Ali following Rick Doblin’s four-decade run. Betty brings decades of experience in drug policy reform, from Colorado’s 2012 cannabis legalization campaign to leading Students for Sensible Drug Policy, and now helps guide MAPS through one of the movement’s most pivotal moments: the FDA’s rejection of Lycos Therapeutics’ MDMA-assisted therapy ap...